# Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

> **NCT06769126** · PHASE2 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 900 (estimated)

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma
- Lung Small Cell Carcinoma, A Subtype
- Lung Small Cell Carcinoma, I Subtype
- Lung Small Cell Carcinoma, N Subtype
- Lung Small Cell Carcinoma, P Subtype

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Ceralasertib
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Durvalumab
- **DRUG:** Etoposide
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Monalizumab
- **DRUG:** Platinum Compound
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Saruparib
- **RADIATION:** Thoracic Radiation Therapy

## Key facts

- **NCT ID:** NCT06769126
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769126, "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06769126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*